Financial Performance - For the fiscal year ending June 30, 2025, the company's revenue was approximately RMB 90.2 million, a significant increase from RMB 47.6 million in the fiscal year 2024, representing an increase of 89.5%[9] - The profit attributable to owners for the fiscal year 2025 was approximately RMB 22.7 million, a decrease from RMB 200 million in the fiscal year 2024, indicating a decline of 88.6%[9] - The total comprehensive income attributable to owners for the fiscal year 2025 was approximately RMB 28.2 million, down from RMB 204 million in the fiscal year 2024, reflecting a decrease of 86.1%[9] - The basic earnings per share for the fiscal year 2025 were RMB 2.75, a significant drop from RMB 29.79 in the fiscal year 2024[9] - Gross profit for fiscal year 2025 was approximately RMB 8,200,000, up from RMB 1,900,000 in fiscal year 2024, with a gross margin of 9.1%, compared to 4.0% in the previous year[21] - The company reported a profit before tax of RMB 23,026,000 for the fiscal year ending June 30, 2025, compared to a profit of RMB 200,020,000 in 2024[45] - The company reported a net profit of RMB 22,711,000 for the year, compared to RMB 200,013,000 in the previous year, indicating a decrease due to prior year's debt restructuring gains[156] - Total comprehensive income for the year was RMB 28,216,000, down from RMB 204,049,000 in 2024, primarily due to the absence of debt restructuring income[156] Revenue Sources - The company completed a total timber harvest of approximately 18,016 cubic meters in the fiscal year 2025, generating timber sales revenue of approximately RMB 36.6 million[13] - The company recorded ginseng sales revenue of approximately RMB 14.5 million in the fiscal year 2025, compared to RMB 2.56 million in the fiscal year 2024, marking an increase of 466.4%[16] - The ginseng business generated total revenue of approximately RMB 39.5 million in the fiscal year 2025, including RMB 25 million from purchased ginseng and RMB 14.5 million from self-cultivated ginseng[16] - The health products manufacturing and trading business recorded revenue of approximately RMB 14.1 million in the fiscal year 2025[17] - In the fiscal year 2025, the company generated revenue of approximately RMB 36.6 million from forestry management, RMB 39.5 million from ginseng business, and RMB 14.1 million from health products[55] Capital Structure and Debt - The capital debt ratio as of June 30, 2025, was approximately 77.3%, a decrease of 15.4 percentage points from 92.7% in the fiscal year 2024[9] - As of June 30, 2025, the company had total assets of approximately RMB 205,400,000 and net assets of approximately RMB 46,700,000[28] - The company has no secured bank borrowings as of June 30, 2025[62] - The company reported a decrease in total liabilities, with cumulative losses amounting to RMB 938,993 thousand as of June 30, 2025[161] Shareholder Information - The company did not recommend any dividend distribution for the fiscal year 2025, consistent with the previous fiscal year[9] - As of June 30, 2025, the company has no distributable reserves available for shareholders, consistent with the previous year[75] - The company has issued at least 25% of its shares to the public as of the fiscal year 2025[73] - The company completed a share consolidation on July 8, 2025, reducing the total issued shares from 859,242,204 to 85,924,220[37] - The company raised approximately HKD 5.85 million through a placement of 143,000,000 new shares at HKD 0.043 per share, increasing the issued share capital by about 16.64%[38] Governance and Management - The board consists of six members, including two women, achieving gender diversity with a target to maintain at least one female director[101] - The company has adopted a board diversity policy, considering various factors such as gender, age, cultural background, and professional experience[99] - The board has reviewed the effectiveness of the board diversity policy and the implementation of the employee diversity policy for the fiscal year 2025[102] - The company has established a management authorization framework, allowing management to execute daily operational responsibilities under the CEO's leadership[108] - The board has a structured approach to continuous professional development for its members, ensuring compliance with corporate governance codes[109] Risk Management - The company faced credit risk primarily from receivables, with a significant portion of bank deposits held in high credit-rated banks, minimizing potential losses[70] - The company maintains sufficient cash and cash equivalents to manage liquidity risk and reduce cash flow volatility[71] - The internal control and risk management systems were reviewed by the Board through the Audit Committee, which found no significant deficiencies and confirmed effective implementation during fiscal year 2025[129] Compliance and Reporting - The financial statements have been prepared in accordance with the Hong Kong Financial Reporting Standards and the disclosure requirements of the Hong Kong Companies Ordinance[139] - The auditor's report does not cover other information included in the annual report, which is the responsibility of the company's directors[148] - The company regularly reviews its corporate governance practices to ensure compliance with established codes and regulations[96] Future Outlook - The company plans to gradually reduce reliance on suppliers for aged ginseng by cultivating its own stock, ensuring quality through genetic consistency with supplier plants[18] - The company successfully cultivated its first batch of Epimedium in June 2024 and expanded its planting area by 28 acres in July 2024, with expected sales by June 2026[19] - The group expects that the new and revised Hong Kong Financial Reporting Standards will not have a significant impact on the consolidated financial statements[171]
中国健康科技集团(01069) - 2025 - 年度财报